These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24016408)

  • 1. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
    Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
    Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
    Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
    Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
    Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
    Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
    Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
    Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
    Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
    Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
    Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
    Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
    J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
    Fader AN; Nagel C; Axtell AE; Zanotti KM; Kelley JL; Moore KN; Secord AA; Walsh CS; Huh WK; Gehrig PA; Gibbons H; Rose PG; Havrilesky LJ; Tuller E; Drake RD; Bottsford-Miller J; O'Malley DM;
    Gynecol Oncol; 2009 Mar; 112(3):558-62. PubMed ID: 19118888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
    Fader AN; Drake RD; O'Malley DM; Gibbons HE; Huh WK; Havrilesky LJ; Gehrig PA; Tuller E; Axtell AE; Zanotti KM;
    Cancer; 2009 May; 115(10):2119-27. PubMed ID: 19306417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
    Hensley ML; Blessing JA; Mannel R; Rose PG
    Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
    Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
    Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
    Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
    Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
    Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
    Friedman CF; Hensley ML
    Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large primary vaginal leiomyosarcoma diagnosed postoperatively and uterine leiomyomas treated with surgery and chemotherapy.
    Tsai HJ; Ruan CW; Kok VC; Li MC
    J Obstet Gynaecol; 2013 Aug; 33(6):643-4. PubMed ID: 23919878
    [No Abstract]   [Full Text] [Related]  

  • 19. Uterine leiomyosarcoma--a Singapore experience.
    Soh LT; Chew SH; Ang L
    Aust N Z J Obstet Gynaecol; 1999 May; 39(2):246-8. PubMed ID: 10755790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
    Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
    Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.